Overview of the drug development pipeline for polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is a hormonal condition, which occurs when a woman’s ovaries or adrenal glands produce more male hormones than normal. PCOS is a common heterogenous endocrine disorder characterized by irregular menses, hyperandrogenism, and polycystic ovaries. It develops cysts (fluid-filled sacs) on the ovaries. It is also known as Stein-Leventhal syndrome. Furthermore, it is one of the most common hormonal endocrine disorders. PCOS is also linked to the development of other medical conditions such as insulin resistance, type 2 diabetes, high cholesterol, high blood pressure, and heart diseases. PCOS is one of the most common causes of female infertility, affecting 6% to 12% of the US women of reproductive age. PCOS is a lifelong health condition that continues far beyond the child-bearing years. As a result, owing to the increase in incidences of PCOS at such an alarming rate, there has been a continuous rise in the drug development for polycystic ovary syndrome.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for polycystic ovary syndrome (PCOS). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of polycystic ovary syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- ADDEX THERAPEUTICS
- CRINETICS PHARMACEUTICALS
- Dexa Medica
- Kindex Pharmaceuticals
- Novartis
Therapeutic assessment of the drug development pipeline for polycystic ovary syndrome by route of administration
The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for polycystic ovary syndrome by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for polycystic ovary syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for polycystic ovary syndrome?
- What are the companies that are currently involved in the development of drug molecules for polycystic ovary syndrome?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX